| Autor: |
Tashkin DP; David Geffen School of Medicine at UCLA Health Sciences, Los Angeles, California, USA., Barjaktarevic I; Department of Medicine, UCLA, Los Angeles, California, USA., Gomez-Seco J; Department of Pulmonology, Fakeeh University Hospital, Dubai, United Arab Emirates., Behbehani NH; Department of Medicine, Kuwait University, Kuwait, Kuwait., Koltun A; Viatris, Inc., Canonsburg, Pennsylvania, USA., Siddiqui UA; Viatris, Inc., Dubai, United Arab Emirates. |
| Jazyk: |
angličtina |
| Zdroj: |
Journal of aerosol medicine and pulmonary drug delivery [J Aerosol Med Pulm Drug Deliv] 2024 Aug; Vol. 37 (4), pp. 189-201. Date of Electronic Publication: 2024 May 29. |
| DOI: |
10.1089/jamp.2023.0016 |
| Abstrakt: |
Background: Chronic obstructive pulmonary disease (COPD) is a preventable, progressive disease and the third leading cause of death worldwide. The epidemiological data of COPD from Gulf countries are very limited, as it remains underdiagnosed and underestimated. Risk factors for COPD include tobacco cigarette smoking, water pipe smoking (Shisha), exposure to air pollutants, occupational dusts, fumes, and chemicals. Inadequate treatment of COPD leads to worsening of disease. The 2024 GOLD guidelines recommend use of inhaled bronchodilators, corticosteroids, and adjunct therapies for treatment and management of COPD patients based on an individual assessment of the severity of symptoms and risk of exacerbations. This article reviews COPD pharmacotherapy in the Gulf countries and explores the role of nebulization in the management of COPD in this region. Methods: To review the COPD pharmacotherapy in the Gulf Countries, literature search was conducted using PubMed, Medline, Cochrane Systematic Reviews, and Google Scholar databases (before December 2022), using search terms such as COPD, nebulization, inhalers/inhalation, aerosols, and Gulf countries. Relevant articles from the reference list of identified studies were reviewed. Consensus statements, expert opinion, and other published review articles were included. Results: In the Gulf countries, pressurized metered-dose inhalers (pMDIs), dry powder inhalers (DPIs), soft mist inhalers, and nebulizers are used for drug delivery to COPD patients. pMDIs and DPIs are most prone to errors in technique and other common device handling errors. Nebulization is another mode of inhalation drug delivery, which is beneficial in certain patient populations such as the elderly and patients with cognitive impairment, motor or neuromuscular disorders, and other comorbidities. Conclusion: There is no major difference between Gulf countries and rest of the world in the approach to management of COPD. Nebulizers should be considered for patients who have difficulties in accessing or using MDIs and DPIs, irrespective of geographical location. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
